[1] |
李小玲,杨泽.阿尔兹海默病致病机制及相关遗传易感基因[J].中国老年保健医学,2019,17(3):90-92.
|
[2] |
姚钱,郑红云,李艳.阿尔兹海默症发病机制研究进展[J].职业与健康,2019,35(15):2153-2156.
|
[3] |
王思翔,曾红梅.核心生物标志物用于阿尔兹海默病诊断的研究进展[J].实用临床医学,2019,20(2):92-95.
|
[4] |
梁兵,袁芳.国际新近阿尔茨海默病痴呆诊断标准解读[J].重庆医科大学学报,2017,42(6):682-683.
|
[5] |
Sabbagh MN,Hendrix S,Harrison JE.FDA position statement "Early Alzheimer′ s disease:Developing drugs for treatment,Guidance for Industry"[J].Alzheimers Dement (N Y),2019,5:13-19.
|
[7] |
邓青芳,马风伟.阿尔兹海默病的发病机制及药物治疗研究进展[J].贵州师范大学学报(自然科学版),2020,38(1):104-111.
|
[11] |
王金春,刘慧影,曹云鹏.tau 蛋白与阿尔茨海默病[J].中国组织工程研究,2020,24(17):2775-2781.
|
[15] |
张群,林思睿,吴琼英,等.神经丝轻链蛋白与神经系统疾病[J].中风与神经疾病杂志,2019,36(4):380-382.
|
[18] |
张嘉泳,柳维林,陈立典,等.神经颗粒素对中枢神经系统疾病认知功能障碍作用的研究进展[J].中国康复理论与实践,2020,26(3):325-329.
|
[6] |
Schindler SE,Sutphen CL,Teunissen C,et al.Upward drift in cerebrospinal fluid amyloid beta 42 assay values for more than 10 years[J].Alzheimers Dement,2018,14(1):62-70.
|
[8] |
Sutphen CL,Jasielec MS,Shah AR,et al.Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age[J].JAMA Neurol,2015,72(9):1029-1042.
|
[9] |
Wang L,Benzinger TL,Hassenstab J,et al.Spatially distinct atrophy is linked to beta-amyloid and tau in preclinical Alzheimer disease[J].Neurology,2015,84(12):1254-1260.
|
[10] |
Schjonning Nielsen M,Simonsen AH,Siersma V,et al.Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting[J].Dement Geriatr Cogn Dis Extra,2016,6(3):465-476.
|
[12] |
Palmqvist S,Zetterberg H,Mattsson N,et al.Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease[J].Neurology,2015,85(14):1240-1249.
|
[13] |
Olsson B,Lautner R,Andreasson U,et al.CSF and blood biomarkers for the diagnosis of Alzheimer′s disease:a systematic review and meta-analysis[J].Lancet Neurol,2016,15(7):673-684.
|
[14] |
Oboudiyat C,Gefen T,Varelas E,et al.Cerebrospinal fluid markers detect Alzheimer′s disease in nonamnestic dementia[J].Alzheimers Dement,2017,13(5):598-601.
|
[16] |
Eratne D,Loi SM,Walia N,et al.A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders:A′C-reactive protein′ for psychiatrists and neurologists?[J].Aust N Z J Psychiatry,2020,54(1):57-67.
|
[17] |
Zhao Y,Xin Y,Meng S,et al.Neurofilament light chain protein in neurodegenerative dementia:A systematic review and network meta-analysis[J].Neurosci Biobehav Rev,2019,102:123-138.
|
[19] |
Headley A,De Leon-Benedetti A,Dong C,et al.Neurogranin as a predictor of memory and executive function decline in MCI patients[J].Neurology,2018,90(10):e887-e895.
|
[20] |
Wellington H,Paterson RW,Portelius E,et al.Increased CSF neurogranin concentration is specific to Alzheimer disease[J].Neurology,2016,86(9):829-835.
|
[21] |
Sweeney MD,Sagare AP,Zlokovic BV.Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders[J].Nat Rev Neurol,2018,14(3):133-150.
|
[22] |
Sagare AP,Sweeney MD,Makshanoff J,et al.Shedding of soluble platelet-derived growth factor receptor-beta from human brain pericytes[J].Neurosci Lett,2015,607:97-101.
|
[23] |
Nation DA,Sweeney MD,Montagne A,et al.Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction[J].Nat Med,2019,25(2):270-276.
|
[24] |
Miners JS,Kehoe PG,Love S,et al.CSF evidence of pericyte damage in Alzheimer′s disease is associated with markers of blood-brain barrier dysfunction and disease pathology[J].Alzheimers Res Ther,2019,11(1):81.
|
[25] |
黄攀,徐敏,何晓英,等.阿尔茨海默病患者外周血microRNA-146a、Aβ1-42 蛋白、tau 蛋白的表达及临床意义[J].中国免疫学杂志,2020,36(7):859-863.
|
[26] |
王治国,战莹,武晓丹,等.血浆和脑脊液Aβ42、tau 水平对阿尔茨海默病患者的早期诊断价值[J].检验医学与临床,2018,15(3):314-316.
|
[27] |
王治国,战莹,武晓丹,等.阿尔茨海默病β 淀粉样蛋白水平监测:11C-PIB PET/CT 显像沉积量与血浆水平的相关性研究[J].中华老年多器官疾病杂志,2018,17(10):725-729.
|
[28] |
Chen Z,Mengel D,Keshavan A,et al.Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer′s disease[J].Alzheimers Dement,2019,15(3):487-496.
|
[29] |
康建华,杨立顺,李娜.血浆总tau 蛋白和磷酸化tau 蛋白在阿尔茨海默病中的诊断意义[J].国际检验医学杂志,2017,38(1):37-38.
|
[30] |
谭兰,谭林,郁金泰,等.阿尔茨海默病外周血生物标志物的研究现状和进展[C].山东省医学会、中国免疫学会神经免疫分会、中华医学会神经病学分会神经免疫学组.山东省2013年神经内科学学术会议暨中国神经免疫大会2013 论文汇编.山东省科学技术协会,2013:57.
|
[31] |
Lin YS,Lee WJ,Wang SJ,et al.Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease[J].Sci Rep,2018,8(1):17 368.
|
[32] |
Mattsson N,Andreasson U,Zetterberg H,et al.Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease[J].JAMA Neurol,2017,74(5):557-566.
|
[33] |
武庆娟,陈恒文,高健,等.外泌体miRNA 在心血管疾病中的研究进展[J].中国病理生理杂志,2020,36(2):371-377.
|
[34] |
Yang TT,Liu CG,Gao SC,et al.The Serum Exosome Derived MicroRNA-135a,-193b,and-384WerePotentialAlzheimer′s Disease Biomarkers[J].Biomed Environ Sci,2018,31(2):87-96.
|
[35] |
Herrera-Espejo S,Santos-Zorrozua B,Alvarez-González P,et al.A Systematic Review of MicroRNA Expression as Biomarker of Late-Onset Alzheimer′s Disease[J].Mol Neurobiol,2019,56(12):8376-8391.
|
[36] |
Wang L,Liu J,Wang Q,et al.MicroRNA-200a-3p Mediates Neuroprotection in Alzheimer-Related Deficits and Attenuates Amyloid-Beta Overproduction and Tau Hyperphosphorylation via Coregulating BACE1 and PRKACB[J].Front Pharmacol,2019,10:806.
|